• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LEKTI片段特异性抑制组织激肽释放酶5、组织激肽释放酶7和组织激肽释放酶14,并通过pH依赖性相互作用控制脱屑。

LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.

作者信息

Deraison Celine, Bonnart Chrystelle, Lopez Frederic, Besson Celine, Robinson Ross, Jayakumar Arumugam, Wagberg Fredrik, Brattsand Maria, Hachem Jean Pierre, Leonardsson Goran, Hovnanian Alain

机构信息

Institut National de la Santé et de la Recherche Médicale, U563, Toulouse, F-31300 France.

出版信息

Mol Biol Cell. 2007 Sep;18(9):3607-19. doi: 10.1091/mbc.e07-02-0124. Epub 2007 Jun 27.

DOI:10.1091/mbc.e07-02-0124
PMID:17596512
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1951746/
Abstract

LEKTI is a 15-domain serine proteinase inhibitor whose defective expression underlies the severe autosomal recessive ichthyosiform skin disease, Netherton syndrome. Here, we show that LEKTI is produced as a precursor rapidly cleaved by furin, generating a variety of single or multidomain LEKTI fragments secreted in cultured keratinocytes and in the epidermis. The identity of these biological fragments (D1, D5, D6, D8-D11, and D9-D15) was inferred from biochemical analysis, using a panel of LEKTI antibodies. The functional inhibitory capacity of each fragment was tested on a panel of serine proteases. All LEKTI fragments, except D1, showed specific and differential inhibition of human kallikreins 5, 7, and 14. The strongest inhibition was observed with D8-D11, toward KLK5. Kinetics analysis revealed that this interaction is rapid and irreversible, reflecting an extremely tight binding complex. We demonstrated that pH variations govern this interaction, leading to the release of active KLK5 from the complex at acidic pH. These results identify KLK5, a key actor of the desquamation process, as the major target of LEKTI. They disclose a new mechanism of skin homeostasis by which the epidermal pH gradient allows precisely regulated KLK5 activity and corneodesmosomal cleavage in the most superficial layers of the stratum corneum.

摘要

LEKTI是一种含有15个结构域的丝氨酸蛋白酶抑制剂,其表达缺陷是严重常染色体隐性鱼鳞病样皮肤病——Netherton综合征的发病基础。在此,我们表明LEKTI以前体形式产生,并迅速被弗林蛋白酶切割,产生多种单结构域或多结构域的LEKTI片段,这些片段分泌于培养的角质形成细胞和表皮中。利用一组LEKTI抗体,通过生化分析推断出这些生物片段(D1、D5、D6、D8 - D11和D9 - D15)的身份。在一组丝氨酸蛋白酶上测试了每个片段的功能抑制能力。除D1外,所有LEKTI片段均对人组织激肽释放酶5、7和14表现出特异性和差异性抑制。观察到D8 - D11对KLK5的抑制作用最强。动力学分析表明,这种相互作用迅速且不可逆,反映出一种极其紧密的结合复合物。我们证明pH变化控制这种相互作用,导致在酸性pH下从复合物中释放出活性KLK5。这些结果确定了脱屑过程的关键因子KLK5是LEKTI的主要靶点。它们揭示了一种皮肤稳态的新机制:表皮pH梯度可精确调节角质层最表层的KLK5活性和角质桥粒裂解。

相似文献

1
LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.LEKTI片段特异性抑制组织激肽释放酶5、组织激肽释放酶7和组织激肽释放酶14,并通过pH依赖性相互作用控制脱屑。
Mol Biol Cell. 2007 Sep;18(9):3607-19. doi: 10.1091/mbc.e07-02-0124. Epub 2007 Jun 27.
2
Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.在人皮肤中鉴定淋巴细胞上皮Kazal型抑制剂2作为激肽释放酶相关肽酶5特异性蛋白酶抑制剂。
PLoS One. 2009;4(2):e4372. doi: 10.1371/journal.pone.0004372. Epub 2009 Feb 3.
3
A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.多种组织激肽释放酶丝氨酸蛋白酶在表皮脱屑中的潜在作用。
J Biol Chem. 2007 Feb 9;282(6):3640-52. doi: 10.1074/jbc.M607567200. Epub 2006 Dec 11.
4
LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.LEKTI 结构域 D6、D7 和 D8+9 可作为转谷氨酰胺酶 1 的底物:对 Netherton 综合征靶向治疗的启示。
Br J Dermatol. 2019 Nov;181(5):999-1008. doi: 10.1111/bjd.17820. Epub 2019 Jun 6.
5
Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. Netherton 综合征缺陷蛋白,LEKTI,在表皮中的蛋白水解激活级联:对皮肤稳态的影响。
J Invest Dermatol. 2011 Nov;131(11):2223-32. doi: 10.1038/jid.2011.174. Epub 2011 Jun 23.
6
Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes.紫外线B对人表皮角质形成细胞中角质桥粒酶表达的二分效应。
J Dermatol Sci. 2009 Apr;54(1):17-24. doi: 10.1016/j.jdermsci.2008.11.004. Epub 2008 Dec 31.
7
LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.LEKTI定位于板层颗粒中,与KLK5和KLK7分离,并分泌到颗粒层浅层的细胞外间隙中。
J Invest Dermatol. 2005 Feb;124(2):360-6. doi: 10.1111/j.0022-202X.2004.23583.x.
8
The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.420K LEKTI 变异改变了 LEKTI 的蛋白水解激活,导致蛋白酶失调:对特应性皮炎的影响。
Hum Mol Genet. 2012 Oct 1;21(19):4187-200. doi: 10.1093/hmg/dds243. Epub 2012 Jun 23.
9
LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.LEKTI在人原代角质形成细胞中的蛋白水解加工、组织分布及Netherton综合征中的表达缺陷
Hum Mol Genet. 2003 Oct 1;12(19):2417-30. doi: 10.1093/hmg/ddg247. Epub 2003 Jul 29.
10
Exonic mutations associated with atopic dermatitis disrupt lympho-epithelial Kazal-type related inhibitor action and enhance its degradation.与特应性皮炎相关的外显子突变会破坏淋巴上皮 Kazal 型相关抑制剂的作用并增强其降解。
Allergy. 2020 Feb;75(2):403-411. doi: 10.1111/all.14018. Epub 2019 Sep 9.

引用本文的文献

1
The SPINK Protein Family in Cancer: Emerging Roles in Tumor Progression, Therapeutic Resistance, and Precision Oncology.癌症中的丝氨酸蛋白酶抑制剂Kazal型相关肽(SPINK)蛋白家族:在肿瘤进展、治疗抗性和精准肿瘤学中的新作用
Pharmaceuticals (Basel). 2025 Aug 13;18(8):1194. doi: 10.3390/ph18081194.
2
Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult.司库奇尤单抗作为一名年轻成年人慢性 Netherton 综合征的新型治疗方法。
Am J Case Rep. 2025 Apr 29;26:e946411. doi: 10.12659/AJCR.946411.
3
Kallikrein-8 mediates furin-independent Activin-A precursor processing to stimulate tumor growth in melanoma.激肽释放酶8介导不依赖弗林蛋白酶的激活素A前体加工,以刺激黑色素瘤中的肿瘤生长。
Nat Commun. 2025 Mar 10;16(1):2354. doi: 10.1038/s41467-025-57661-5.
4
Developing a Core Outcome Set for Netherton Syndrome: An International Multi-Stakeholder e-Delphi Consensus Study.制定 Netherton 综合征核心结局集:一项国际多利益相关方电子德尔菲共识研究
Dermatology. 2025;241(1):35-48. doi: 10.1159/000542215. Epub 2024 Nov 1.
5
Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome.多糖、缀合和基于 mRNA 的疫苗在 Netherton 综合征患者中具有免疫原性。
J Clin Immunol. 2024 Oct 30;45(1):36. doi: 10.1007/s10875-024-01828-0.
6
Revisiting the human umbilical cord epithelium. An atypical epithelial sheath with distinctive features.重新审视人脐带上皮。一种具有独特特征的非典型上皮鞘。
Cell Tissue Res. 2024 Dec;398(3):175-189. doi: 10.1007/s00441-024-03920-8. Epub 2024 Oct 16.
7
Interleukin-36 Is Highly Expressed in Skin Biopsies from Two Patients with Netherton Syndrome.白细胞介素-36在两名Netherton综合征患者的皮肤活检组织中高表达。
Dermatopathology (Basel). 2024 Aug 12;11(3):230-237. doi: 10.3390/dermatopathology11030024.
8
Recombinant scFv-Fc Anti-kallikrein 7 Antibody-Loaded Thermosensitive Hydrogels Against Skin Desquamation Disorders.重组 scFv-Fc 抗激肽释放酶 7 抗体负载的热敏水凝胶治疗皮肤脱屑障碍。
ACS Appl Bio Mater. 2024 Jul 15;7(7):4486-4496. doi: 10.1021/acsabm.4c00371. Epub 2024 Jun 17.
9
Three stepwise pH progressions in stratum corneum for homeostatic maintenance of the skin.皮肤维持稳态的角质层中存在三个逐步变化的 pH 值梯度。
Nat Commun. 2024 May 15;15(1):4062. doi: 10.1038/s41467-024-48226-z.
10
Higher Expression of Lympho-epithelial Kazal-type-Related Inhibitor-1 Fragments and Decreased Desquamation in the Lesional Skin of Nummular Eczema.结节性湿疹皮损中淋巴上皮 Kazal 型相关抑制剂-1 片段表达升高和脱屑减少。
Acta Derm Venereol. 2024 Mar 29;104:adv188636. doi: 10.2340/actadv.v104.18636.

本文引用的文献

1
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences.七种人组织激肽释放酶的特异性分析揭示了各自的亚位点偏好。
J Biol Chem. 2006 Sep 1;281(35):25678-88. doi: 10.1074/jbc.M602372200. Epub 2006 Jun 1.
2
Serine protease signaling of epidermal permeability barrier homeostasis.表皮通透屏障稳态的丝氨酸蛋白酶信号传导
J Invest Dermatol. 2006 Sep;126(9):2074-86. doi: 10.1038/sj.jid.5700351. Epub 2006 May 11.
3
Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome.角质形成细胞桥粒钙黏蛋白是Netherton综合征中角质层胰蛋白酶样和糜蛋白酶样活性亢进的优先作用靶点。
J Invest Dermatol. 2006 Jul;126(7):1622-32. doi: 10.1038/sj.jid.5700284. Epub 2006 Apr 20.
4
SPINK5, the defective gene in netherton syndrome, encodes multiple LEKTI isoforms derived from alternative pre-mRNA processing.SPINK5是 Netherton 综合征中的缺陷基因,它编码多种通过前体mRNA可变剪接产生的LEKTI亚型。
J Invest Dermatol. 2006 Feb;126(2):315-24. doi: 10.1038/sj.jid.5700015.
5
hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6.人皮肤中含量丰富的两种丝氨酸蛋白酶hK5和hK7,被LEKTI结构域6所抑制。
Br J Dermatol. 2005 Dec;153(6):1200-3. doi: 10.1111/j.1365-2133.2005.06834.x.
6
Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).丝氨酸蛋白酶抑制剂淋巴细胞上皮Kazal型抑制剂(LEKTI)对人组织激肽释放酶5和7的抑制作用。
Biol Chem. 2005 Nov;386(11):1173-84. doi: 10.1515/BC.2005.134.
7
Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity.pH值长期升高导致丝氨酸蛋白酶持续活性,进而引起脂质加工酶降解以及屏障功能和角质层完整性的深刻改变。
J Invest Dermatol. 2005 Sep;125(3):510-20. doi: 10.1111/j.0022-202X.2005.23838.x.
8
Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases.多种组织激肽释放酶在正常皮肤及皮肤疾病中的mRNA和蛋白表达
Br J Dermatol. 2005 Aug;153(2):274-81. doi: 10.1111/j.1365-2133.2005.06754.x.
9
Consequences of C-terminal domains and N-terminal signal peptide deletions on LEKTI secretion, stability, and subcellular distribution.C末端结构域和N末端信号肽缺失对LEKTI分泌、稳定性及亚细胞分布的影响。
Arch Biochem Biophys. 2005 Mar 1;435(1):89-102. doi: 10.1016/j.abb.2004.12.012.
10
LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.LEKTI定位于板层颗粒中,与KLK5和KLK7分离,并分泌到颗粒层浅层的细胞外间隙中。
J Invest Dermatol. 2005 Feb;124(2):360-6. doi: 10.1111/j.0022-202X.2004.23583.x.